537 related articles for article (PubMed ID: 24608574)
1. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Fritsch C; Huang A; Chatenay-Rivauday C; Schnell C; Reddy A; Liu M; Kauffmann A; Guthy D; Erdmann D; De Pover A; Furet P; Gao H; Ferretti S; Wang Y; Trappe J; Brachmann SM; Maira SM; Wilson C; Boehm M; Garcia-Echeverria C; Chene P; Wiesmann M; Cozens R; Lehar J; Schlegel R; Caravatti G; Hofmann F; Sellers WR
Mol Cancer Ther; 2014 May; 13(5):1117-29. PubMed ID: 24608574
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A
Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
[TBL] [Abstract][Full Text] [Related]
4. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Juric D; Castel P; Griffith M; Griffith OL; Won HH; Ellis H; Ebbesen SH; Ainscough BJ; Ramu A; Iyer G; Shah RH; Huynh T; Mino-Kenudson M; Sgroi D; Isakoff S; Thabet A; Elamine L; Solit DB; Lowe SW; Quadt C; Peters M; Derti A; Schegel R; Huang A; Mardis ER; Berger MF; Baselga J; Scaltriti M
Nature; 2015 Feb; 518(7538):240-4. PubMed ID: 25409150
[TBL] [Abstract][Full Text] [Related]
5. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
6. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.
Xu YC; Wang X; Chen Y; Chen SM; Yang XY; Sun YM; Geng MY; Ding J; Meng LH
Theranostics; 2017; 7(4):974-986. PubMed ID: 28382169
[TBL] [Abstract][Full Text] [Related]
7. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
8. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
9. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
[TBL] [Abstract][Full Text] [Related]
10. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
12. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.
Stanland LJ; Ang HX; Hoj JP; Chu Y; Tan P; Wood KC; Luftig MA
Mol Cancer Res; 2023 Nov; 21(11):1148-1162. PubMed ID: 37493631
[TBL] [Abstract][Full Text] [Related]
13. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Liu N; Rowley BR; Bull CO; Schneider C; Haegebarth A; Schatz CA; Fracasso PR; Wilkie DP; Hentemann M; Wilhelm SM; Scott WJ; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2013 Nov; 12(11):2319-30. PubMed ID: 24170767
[TBL] [Abstract][Full Text] [Related]
14. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Bosch A; Li Z; Bergamaschi A; Ellis H; Toska E; Prat A; Tao JJ; Spratt DE; Viola-Villegas NT; Castel P; Minuesa G; Morse N; Rodón J; Ibrahim Y; Cortes J; Perez-Garcia J; Galvan P; Grueso J; Guzman M; Katzenellenbogen JA; Kharas M; Lewis JS; Dickler M; Serra V; Rosen N; Chandarlapaty S; Scaltriti M; Baselga J
Sci Transl Med; 2015 Apr; 7(283):283ra51. PubMed ID: 25877889
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.
Zhang H; Chen D; Ringler J; Chen W; Cui QC; Ethier SP; Dou QP; Wu G
Cancer Res; 2010 May; 70(10):3996-4004. PubMed ID: 20424113
[TBL] [Abstract][Full Text] [Related]
16. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Ihle NT; Lemos R; Wipf P; Yacoub A; Mitchell C; Siwak D; Mills GB; Dent P; Kirkpatrick DL; Powis G
Cancer Res; 2009 Jan; 69(1):143-50. PubMed ID: 19117997
[TBL] [Abstract][Full Text] [Related]
18. Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
Mizrachi A; Shamay Y; Shah J; Brook S; Soong J; Rajasekhar VK; Humm JL; Healey JH; Powell SN; Baselga J; Heller DA; Haimovitz-Friedman A; Scaltriti M
Nat Commun; 2017 Feb; 8():14292. PubMed ID: 28194032
[TBL] [Abstract][Full Text] [Related]
19. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Elkabets M; Pazarentzos E; Juric D; Sheng Q; Pelossof RA; Brook S; Benzaken AO; Rodon J; Morse N; Yan JJ; Liu M; Das R; Chen Y; Tam A; Wang H; Liang J; Gurski JM; Kerr DA; Rosell R; Teixidó C; Huang A; Ghossein RA; Rosen N; Bivona TG; Scaltriti M; Baselga J
Cancer Cell; 2015 Apr; 27(4):533-46. PubMed ID: 25873175
[TBL] [Abstract][Full Text] [Related]
20. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
